Advertisement
Table 3 Implant survival in autogenous bone grafts placed in vascularised and non-vascularised bone grafts
| Non-vascularised bone graft | Vascularised bone graft | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Author | Year of publication | No. of patients who had implants placed into non-vascularised autogenous bone grafts (and failures) | Overall patient implant survival in non-vascularised autogenous bone grafts | No. of implants placed into non-vascularised autogenous bone grafts (and failures) | Overall implant survival in non-vascularised autogenous bone grafts | No. of patients who had implants placed into vascularized autogenous bone grafts (and failures) | Overall patient implant survival in vascularised autogenous bone grafts | No. of implants placed into vascularised autogenous bone grafts (and failures) | Overall implant survival in vascularised autogenous bone grafts |
| Studies with an average follow-up of 3 years or greater | |||||||||
| Watzinger et al. [29] | 1996 | Not reported | N/A | 33 (13) | 60.6%* | Not reported | N/A | 19 (1) | 94.7%* |
| Teoh et al. [26] | 2005 | N/A | N/A | N/A | N/A | 22 (2) | 90.9%* | 71 (3) | 95.8%* |
| Wu et al. [30] | 2008 | N/A | N/A | N/A | N/A | 29 (not reported) | N/A | 100 (9) | 91% |
| Fenlon et al. [19] | 2012 | N/A | N/A | N/A | N/A | 41 (10) | 75.6%* | 145 (18) | 87.5%* |
| Ch’ng et al. [20] | 2014 | N/A | N/A | N/A | N/A | 54 (10) | 81.5%* | 243 (20) | 91.8% |
| Shaw et al. [31] | 2005 | 2 (1) | 50%* | 8 (2) | 75%* | 31 (11) | 64.5%* | 115 (30) | 73.9%* |
| Wang et al. [21] | 2015 | N/A | N/A | N/A | N/A | 19 (0) | 100% | 51 (0) | 100%* |
| Yerit et al. [16] | 2006 | Not reported | N/A | Not reported | N/A | Not reported | N/A | Not reported | N/A |
| Linsen et al. [17] | 2009 | Not reported | N/A | 79 (8) | 89.9%* | N/A | N/A | N/A | N/A |
| Studies with an average follow-up of less than 3 years or no average follow-up reported | |||||||||
| Fierz et al. [25] | 2013 | N/A | N/A | N/A | N/A | Not reported | N/A | Not reported | N/A |
| Barrowman et al. [7] | 2011 | Not reported | N/A | 6 (0) | 100%* | Not reported | N/A | 32 (5) | 84.4%* |
| Zou et al. [22] | 2013 | N/A | N/A | N/A | N/A | 32 (not reported) | N/A | 110 (5) | 96.4% |
| Schultes et al. [15] | 2002 | N/A | N/A | N/A | N/A | 38 (2) | 94.7%* | 96 (2) | 97.9%* |
| Buddula et al. [24] | 2010 | Not reported | N/A | Not reported | N/A | Not reported | N/A | Not reported | N/A |
| Klein et al. [32] | 2009 | Not reported | N/A | 128 (22) | 82.8%* | N/A | N/A | N/A | N/A |
| Burgess et al. [27] | 2017 | N/A | N/A | N/A | N/A | 59 (not reported) | N/A | 199 (11) | 93.6% |
| Chiapasco et al. [18] | 2006 | N/A | N/A | N/A | N/A | 14 (1) | 92.9%* | 62 (1) | 98.3%* |
| Chiapasco et al. [23] | 2008 | 16 (1) | 93.8%* | 60 (2) | 96.7%* | N/A | N/A | N/A | N/A |
| Chiapasco et al. [33] | 2000 | 10 (1) | 90%* | 41 (2) | 95.1%* | 8 (1) | 87.5%* | 31 (1) | 96.8%* |
| Hessling et al. [28] | 2015 | Not Reported | N/A | 62 (4) | 93.5%* | Not reported | N/A | 31 (4) | 87.1%* |
